Ridgewood Investments LLC Sells 648 Shares of Solventum Co. (NYSE:SOLV)

Ridgewood Investments LLC trimmed its holdings in shares of Solventum Co. (NYSE:SOLV) by 44.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 821 shares of the company’s stock after selling 648 shares during the period. Ridgewood Investments LLC’s holdings in Solventum were worth $54,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Hollencrest Capital Management bought a new stake in shares of Solventum during the 2nd quarter worth $25,000. Modus Advisors LLC bought a new stake in Solventum in the 4th quarter valued at about $25,000. Copeland Capital Management LLC bought a new stake in Solventum in the 3rd quarter valued at about $26,000. Mather Group LLC. bought a new stake in Solventum in the 3rd quarter valued at about $27,000. Finally, GHP Investment Advisors Inc. bought a new stake in Solventum in the 2nd quarter valued at about $29,000.

Solventum Trading Down 2.6 %

SOLV stock opened at $67.19 on Friday. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $96.05. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The stock has a 50-day simple moving average of $69.32 and a two-hundred day simple moving average of $64.80.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on SOLV shares. Morgan Stanley boosted their price objective on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Piper Sandler boosted their price objective on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. Stifel Nicolaus started coverage on Solventum in a research note on Tuesday, October 8th. They issued a “buy” rating and a $82.00 price objective on the stock. Mizuho assumed coverage on Solventum in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price objective on the stock. Finally, Wolfe Research assumed coverage on Solventum in a report on Thursday, September 26th. They set a “peer perform” rating for the company. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, Solventum currently has an average rating of “Hold” and a consensus target price of $68.29.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.